Inhalable Dry Powder of Bedaquiline for Pulmonary Tuberculosis: In Vitro Physicochemical Characterization, Antimicrobial Activity and Safety Studies

Bedaquiline is a newly developed anti-tuberculosis drug, conditionally approved by the United States Food and Drug Administration (USFDA) for treating drug-resistant tuberculosis in adults. Oral delivery of bedaquiline causes severe side effects such as increased hepatic aminotransferase levels and...

Повний опис

Бібліографічні деталі

Автори:	Mohammad A. M. Momin, Bhamini Rangnekar, Shubhra Sinha, Chen-Yi Cheung, Gregory M. Cook, Shyamal C. Das
Формат:	Artigo
Мова:	Inglês
Опубліковано:	MDPI AG 2019-10-01
Серія:	Pharmaceutics
Предмети:	bedaquiline inhalation formulation spray-drying dry powder tuberculosis
Онлайн доступ:	https://www.mdpi.com/1999-4923/11/10/502
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!